Loading…

Molecular epidemiology of HTLV-2 infection among intravenous drug users in Spain

HTLV-2 infection is prevalent among intravenous drug users (IDUs), which often are coinfected with HIV-1. Two main subtypes, HTLV-2a and -2b, have been described among European IDUs, with a characteristically geographic distribution: IIa in northern Europe and IIb in the south. Although frequent tra...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical virology 2005-05, Vol.33 (1), p.65-70
Main Authors: Toro, Carlos, Rodés, Berta, Bassani, Sylvina, Jiménez, Victoria, Tuset, Concepción, Brugal, María Teresa, Fuente, Luis de la, Soriano, Vincent
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:HTLV-2 infection is prevalent among intravenous drug users (IDUs), which often are coinfected with HIV-1. Two main subtypes, HTLV-2a and -2b, have been described among European IDUs, with a characteristically geographic distribution: IIa in northern Europe and IIb in the south. Although frequent traveling within Europe might have favoured a wide dissemination of diverse HTLV-2 variants, HTLV-2b was so far the only subtype reported in Spain. To investigate the current molecular epidemiology of HTLV-2 in Spain. Twenty-six new HTLV-2 strains isolated from IDUs over the last 11 years in different geographic regions were examined. The HTLV LTR region (620 bp) was sequenced and phylogenetic analyses were performed. Endonuclease restriction sites were examined to further characterize the HTLV-2 subgroup. All 26 individuals infected with HTLV-2 showed viruses belonging to the HTLV-2 b4 clade and were closely related to the previously reported HTLV-2 Spanish and Italian IDU isolates. HTLV-2 subtype b4 continues to be the only HTLV-2 subgroup recognized so far in Spain and no introduction of other HTLV-2 variants has occurred over the last 11 years.
ISSN:1386-6532
1873-5967
DOI:10.1016/j.jcv.2004.10.004